文献速递慢性肾脏病肾小球疾病

恩格列净与非奈利酮联合治疗中急性eGFR变化及其对白蛋白尿降低的中介作用

Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.
PubMed 文献 · J Am Soc Nephrol · 2026-03-29

该研究基于CONFIDENCE试验的预设分析,纳入790例2型糖尿病合并CKD及白蛋白尿患者,随机接受恩格列净、非奈利酮或两者联用。结果显示联合治疗组急性eGFR下降幅度最大(-6.6 ml/min/1.73m²),且急性eGFR下降与联合治疗、基线eGFR较高及使用利尿剂显著相关;急性eGFR变化介导了部分UACR降低效应。

要点

  • 联合治疗组急性eGFR下降大于单药组,且变化可逆。
  • 基线eGFR较高和使用利尿剂者急性eGFR下降更明显。
  • 急性eGFR变化部分介导UACR降低,但非奈利酮附加效应主要非血流动力学。

核心结论

  • 急性eGFR下降与联合治疗、基线eGFR较高及基线使用利尿剂显著相关。
  • 非奈利酮对恩格列净的附加UACR降低效应为非血流动力学介导。
  • 恩格列净降低UACR部分由eGFR变化驱动。

研究设计与样本

  • CONFIDENCE试验的预设分析,纳入790例2型糖尿病合并CKD及白蛋白尿患者。
  • 患者随机1:1:1接受恩格列净、非奈利酮或两者联用,均接受稳定剂量RAS抑制剂。
  • 主要结局为第180天UACR较基线的变化。

主要发现

  • 联合治疗组平均急性eGFR下降为-6.6 ml/min/1.73m²,非奈利酮组为-2.1 ml/min/1.73m²,恩格列净组为-4.8 ml/min/1.73m²,P<0.001。
  • 基线eGFR较高和基线使用利尿剂者急性eGFR下降更显著(两者P<0.001)。
  • 基线收缩压和UACR对急性eGFR下降无统计学显著影响。
  • 急性eGFR变化介导了非奈利酮基础上加用恩格列净对第180天UACR降低效应的28%,而恩格列净基础上加用非奈利酮仅介导5.2%。
  • 所有治疗组AKI均不常见。

临床怎么用

  • 联合治疗时急性eGFR下降更明显,但多可逆,不应因此中断治疗。
  • 基线eGFR较高或使用利尿剂者应关注急性eGFR变化。
  • 非奈利酮联合恩格列净的UACR降低主要不依赖eGFR变化。

局限性

  • 急性eGFR变化的中介分析为探索性分析。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: We investigated the effect of empagliflozin, finerenone, and their combination on eGFR decline in people with type 2 diabetes and albuminuria. Acute declines in eGFR occurred more in those on combination therapy, on diuretics, and with higher eGFR; eGFR changes were reversible. Finerenone's additive effect to empagliflozin on urinary albumin-to-creatinine ratio lowering was nonhemodynamic; empagliflozin lowered urinary albumin-to-creatinine ratio in part driven by eGFR change. BACKGROUND: eGFR decline is common with sodium-glucose cotransporter 2 inhibitors and renin-angiotensin system inhibitors, often prompting treatment interruption or cessation, limiting cardiorenal benefits. This mostly prespecified COmbinatioN effect of FInerenone anD EmpaglifloziN in Participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial analysis investigated the effect of empagliflozin, finerenone, and their combination on change from baseline in eGFR and its determinants and the relationship of change in eGFR with albuminuria reduction in people with type 2 diabetes and CKD. METHODS: Evaluable participants ( N =790) with type 2 diabetes, CKD, and albuminuria, receiving stable doses of renin-angiotensin system inhibitors, were randomized 1:1:1 to empagliflozin, finerenone, or both. The primary outcome was urinary albumin-to-creatinine ratio (UACR) change from baseline to day 180. We assessed mean eGFR change from baseline at day 14 (acute), determinants of acute eGFR decline, and acute eGFR change from baseline as a mediator of UACR reduction at day 180. RESULTS: The mean acute eGFR decline was greater with combination therapy (-6.6 ml/min per 1.73 m 2 ) than with finerenone (-2.1 ml/min per 1.73 m 2 ) or empagliflozin (-4.8 ml/min per 1.73 m 2 ) monotherapy; P < 0.001. Acute decline in eGFR was significantly more pronounced among participants with higher baseline eGFR and in those receiving diuretics at baseline ( P < 0.001 for both factors). Baseline values for systolic BP and UACR had no statistically significant effect on acute eGFR decline. Exploratory analysis showed that acute eGFR change mediated 28% of the effect of adding empagliflozin to finerenone on UACR reduction at day 180 but only 5.2% of the effect when adding finerenone to empagliflozin. AKI was uncommon in all treatment groups. CONCLUSIONS: Acute eGFR decline was significantly associated with combination therapy, higher baseline eGFR, and diuretic use at baseline. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT05254002 .

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Agarwal R, Correa-Rotter R, Navaneethan SD, et al. Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone. J Am Soc Nephrol. 2026. PMID: 41905767. doi:10.1681/ASN.0000001071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。